Impact of ABO blood type on outcomes in patients with primary nonmuscle invasive bladder cancer.

[1]  M. Babjuk,et al.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. , 2013, European urology.

[2]  Tianyuan Xu,et al.  Predicting recurrence and progression in Chinese patients with nonmuscle-invasive bladder cancer using EORTC and CUETO scoring models. , 2013, Urology.

[3]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[4]  L. Martínez-Piñeiro,et al.  The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables. , 2011, European urology.

[5]  H. Herr.  Is repeat transurethral resection needed for minimally invasive T1 urothelial cancer? Pro. , 2011, The Journal of urology.

[6]  L. Martínez-Piñeiro,et al.  Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. , 2009, The Journal of urology.

[7]  Ewout W. Steyerberg,et al.  Prognostic Models With Competing Risks: Methods and Application to Coronary Risk Prediction , 2009, Epidemiology.

[8]  Mark I. McCarthy,et al.  A Genome-Wide Association Study Identifies Protein Quantitative Trait Loci (pQTLs) , 2008, PLoS genetics.

[9]  Å. Borg,et al.  Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q , 2006, Oncogene.

[10]  J Alfred Witjes,et al.  Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. , 2006, European urology.

[11]  C. Marsit,et al.  Loss of heterozygosity on chromosome 9q and p53 alterations in human bladder cancer , 2005, Cancer.

[12]  M. Yazer.  What a difference 2 nucleotides make: a short review of ABO genetics. , 2005, Transfusion medicine reviews.

[13]  S. Hirohashi,et al.  Loss of blood group A antigen expression in bladder cancer caused by allelic loss and/or methylation of the ABO gene , 2005, Laboratory Investigation.

[14]  H. Eiberg,et al.  Genetic and epigenetic alterations of the blood group ABO gene in oral squamous cell carcinoma , 2004, International journal of cancer.

[15]  S. Hakomori,et al.  Glycosylation defining cancer malignancy: New wine in an old bottle , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[16]  H. Herr,et al.  The value of a second transurethral resection in evaluating patients with bladder tumors. , 2000, The Journal of urology.

[17]  S. Hakomori.  Antigen structure and genetic basis of histo-blood groups A, B and O: their changes associated with human cancer. , 1999, Biochimica et biophysica acta.

[18]  C. Cordon-Cardo,et al.  Genotypic and phenotypic characterization of the histoblood group ABO(H) in primary bladder tumors , 1998, International journal of cancer.

[19]  K. Handa,et al.  Histo-blood group A/B versus H status of human carcinoma cells as correlated with haptotactic cell motility: approach with A and B gene transfection. , 1997, Cancer research.

[20]  H. Wolf,et al.  The blood group ABO gene transcript is down-regulated in human bladder tumors and growth-stimulated urothelial cell lines. , 1996, Cancer research.

[21]  M. Raitanen,et al.  Relationship between blood groups and tumour grade, number, size, stage, recurrence and survival in patients with transitional cell carcinoma of the bladder. , 1993, Scandinavian journal of urology and nephrology.

[22]  G. Server,et al.  ABO blood groups and bladder carcinoma. , 1990, European urology.

[23]  E. Orihuela,et al.  Influence of blood group type on the natural history of superficial bladder cancer. , 1987, The Journal of urology.

[24]  S. Hoisington,et al.  Relationship of blood groups and bladder cancer. , 1986, The Journal of urology.

[25]  A. Newman,et al.  Cell surface A, B, or O(H) blood group antigens as an indicator of malignant potential in stage A bladder carcinoma. , 1980, The Journal of urology.